BioCardia, Inc. (BCDA) stock

BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30

$0.83+0.01 (+0.61%)

Close on Nov 13, 2026Market cap $12.58MP/E –Yield –

BioCardia pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

BioCardia's pe ratio was 991.8× on Mar 28, 2013, against 200.2× a year earlier.

Period	Period end	Value	Change (pts)
2013	Mar 28, 2013	991.8×	+961.3
2012	Jul 31, 2012	30.4×	+20.0
2011	Dec 30, 2011	10.4×	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is BCDA.

Revenue growth-100.0% · median -50.0%

Advertisement
300 × 250

See a number that looks wrong?